



NEWS RELEASE

MDxHealth Licensee Exact Sciences Confirms Use of Biomarker and Methylation Technology in its Advanced Colon Cancer Test

DURHAM, NC, and LIEGE, BELGIUM – January 10, 2011 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that Exact Sciences (Nasdaq: EXAS) has confirmed that it is using an MDxHealth methylation biomarker together with MDxHealth's methylation specific PCR (MSP) platform in Cologuard™, a non-invasive stool-based DNA colon cancer screening test. This confirmation has triggered a milestone payment to MDxHealth from Exact Sciences. MDxHealth will also receive royalties on net sales once the test is commercialized. Under the terms of a licensing agreement announced in August 2010, Exact Sciences has been evaluating several MDxHealth methylation biomarkers, among other markers, as well as the MSP technology in studies with its stool-based colon cancer test.

In October 2010, Exact Sciences presented positive data from a study involving samples from 1,100 patients demonstrating the ability of Cologuard to detect 64 percent of colorectal pre-cancers and 85 percent of colorectal cancers. Exact Sciences is now preparing to enroll several thousand patients in a prospective trial to obtain approval from the U.S. Food and Drug Administration. Trial completion is expected in 2012 and the test, if approved, could be launched soon after.

"Following the promising Cologuard data presented in October, confirmation that our biomarker and MSP technology have been incorporated is a significant event for MDxHealth as it further validates our core capabilities," said Dr. Jan Groen, Chief Executive Officer of MDxHealth. "Exact Sciences has a unique focus on colon cancer and is well positioned to ensure patients will benefit from this important colon cancer screening test in the near term."

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research centers such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders.

MDxHealth to present today at Biotech Showcase in San Francisco

MDxHealth will present at the Biotech Showcase Conference in San Francisco, on Monday, Jan. 10, 2011. Dr. Jan Groen, chief executive officer, will make a formal presentation on the company at 2 p.m. Pacific time. The Biotech Showcase runs parallel to the 28th Annual J.P. Morgan Healthcare Conference, and takes place at Parc 55 Wyndham San Francisco - Union Square.

MDxHealth is now on Twitter

Key topics and information linked to MDxHealth activities will be uploaded on Twitter and available for reading to the MDxHealth followers. Tweets will be generated on a regular basis.

In order to keep you updated on events and activities in the field of interest of MDxHealth, we kindly invite you to be a follower of MDxHealth on Twitter. To do so please follow the instructions below:

Go to www.twitter.com

Sign up and create your account.

You will get an e-mail where you have to confirm to have full access to twitter.

Go to www.twitter.com/mdxhealth and push the bottom “ + Follow”

Now you should be a Follower of MDxHealth. Please join us in this new experience.

For more information:

Dr. Jan Groen, CEO
MDxHealth
+32 4 364 20 70

Hans Herklots
Capricorn One
+41 79 598 7149

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation